205 related articles for article (PubMed ID: 37037322)
1. Increasing FDA-accelerated approval of single-arm trials in oncology (1992 to 2020).
Ribeiro TB; Bennett CL; Colunga-Lozano LE; Araujo APV; Hozo I; Djulbegovic B
J Clin Epidemiol; 2023 Jul; 159():151-158. PubMed ID: 37037322
[TBL] [Abstract][Full Text] [Related]
2. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
[TBL] [Abstract][Full Text] [Related]
3. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
4. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
Chen EY; Raghunathan V; Prasad V
JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
[TBL] [Abstract][Full Text] [Related]
5. Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias.
Ribeiro TB; Colunga-Lozano LE; Araujo APV; Bennett CL; Hozo I; Djulbegovic B
J Clin Epidemiol; 2022 Aug; 148():193-195. PubMed ID: 35093531
[TBL] [Abstract][Full Text] [Related]
6. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of Anticancer Drugs Approved Under the Accelerated Approval Program in the US: Success or Failure in Converting to Regular Approval.
Oda Y; Narukawa M
Ther Innov Regul Sci; 2024 Mar; 58(2):387-394. PubMed ID: 38175382
[TBL] [Abstract][Full Text] [Related]
8. US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018.
Omae K; Onishi A; Sahker E; Furukawa TA
JAMA Netw Open; 2022 Sep; 5(9):e2230973. PubMed ID: 36083581
[TBL] [Abstract][Full Text] [Related]
9. National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval.
Cliff ERS; Rome RS; Kesselheim AS; Rome BN
JAMA Netw Open; 2023 Nov; 6(11):e2343285. PubMed ID: 37962889
[TBL] [Abstract][Full Text] [Related]
10. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.
Beaver JA; Howie LJ; Pelosof L; Kim T; Liu J; Goldberg KB; Sridhara R; Blumenthal GM; Farrell AT; Keegan P; Pazdur R; Kluetz PG
JAMA Oncol; 2018 Jun; 4(6):849-856. PubMed ID: 29494733
[TBL] [Abstract][Full Text] [Related]
11. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
[TBL] [Abstract][Full Text] [Related]
12. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.
Liu ITT; Kesselheim AS; Cliff ERS
JAMA; 2024 May; 331(17):1471-1479. PubMed ID: 38583175
[TBL] [Abstract][Full Text] [Related]
13. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
Hilal T; Sonbol MB; Prasad V
JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
Gyawali B; Hey SP; Kesselheim AS
JAMA Intern Med; 2019 Jul; 179(7):906-913. PubMed ID: 31135808
[TBL] [Abstract][Full Text] [Related]
16. Oncology's trial and error: Analysis of the FDA withdrawn accelerated approvals.
Preziosi AJ; Priefer R
Life Sci; 2024 Jun; 346():122615. PubMed ID: 38582392
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of Randomized Controlled Trials for Cancer Drugs Approved by the Food and Drug Administration Based on Single-Arm Studies.
Rittberg R; Czaykowski P; Niraula S
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409254
[TBL] [Abstract][Full Text] [Related]
18. Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies.
Ladanie A; Speich B; Briel M; Sclafani F; Bucher HC; Agarwal A; Ioannidis JPA; Pereira TV; Kasenda B; Hemkens LG
J Clin Epidemiol; 2019 Oct; 114():49-59. PubMed ID: 31158450
[TBL] [Abstract][Full Text] [Related]
19. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.
Tibau A; Ocana A; Anguera G; Seruga B; Templeton AJ; Barnadas A; Amir E
JAMA Oncol; 2016 Jun; 2(6):744-50. PubMed ID: 26940233
[TBL] [Abstract][Full Text] [Related]
20. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
Chen EY; Joshi SK; Tran A; Prasad V
JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
